Simeng Zhu retweeted
LINACS is online!
What? Living Systematic Review on Safety of Stereotactic RT ⚡️+ Novel Anticancer Drug 💊
Published url.de.m.mimecastprotect.com…
Online Database: linacs.net
Housed in @ESTRO_RT @EORTC Oligocare consortium
Updated every 6 mo 🔄
🧵
Simeng Zhu retweeted
Fairly easy actions I use to reduce phone addiction:
1. Never bring phone in the bedroom
2. If going out to a meal walking distance from home, leave phone behind
3. Black and white mode toggle on Home Screen
4. Silly one: move phone out of pockets I like to put my hands in
Simeng Zhu retweeted
TMLR has faced a deluge of submissions, necessitating stricter desk rejection policies due to limited reviewer capacity
Co-EiC Nihar Shah reached out to authors of 10 papers slated for desk reject. Could they answer questions about their *own* submission?
medium.com/@TmlrOrg/asking-a…
Simeng Zhu retweeted
Eric Miller Leads International Trial Exploring Total Ablative Therapy for Limited Metastatic Colorectal Cancer oncodaily.com/voices/eric-mi…
Simeng Zhu retweeted
The bolus versus weekly cisplatin debate rages on, but fortunately more data dropped this past week with the publication of the ConCERT trial (Concurrent Chemotherapy and External Radiation Therapy) comparing bolus with weekly schedules.
Some thoughts on this trial and the cisplatin schedules below.
academic.oup.com/jnci/articl…
Simeng Zhu retweeted
Apparently, yesterday @midjourney pivoted from AI image generation to...whole body ultrasound , presumably AI-augmented. I spent some time trying to find hard data and did not come up with much beyond the video. Some thoughts based on the X reactions today.
1) "Nobody's ever done this before." This seems to be a variant on ultrasound tomography, with Butterfly sensors arranged in rings. Ultrasound tomography is not new, with commercial systems available for breast imaging. The system proposed here seems very similar to Garrett et al 2024 (pmc.ncbi.nlm.nih.gov/article…) which provided fuzzy images of the abdomen and extremity. By collating sound wave return from the ring array the system can attempt to minimize artifact from bone and gas. So, we have known this is possible since 2024.
2) "So easy for the patient." The system requires the patient to submerge themselves in water. For commercial breast UT, this simply requires laying on top of a shaped tank, but not going fully in water. As some people have difficulty lying on a DEXA or CT scanner (the latter of which can image in seconds) I will be interested to see how this is received by patients.
3) "This will revolutionize medical imaging." Ultrasound is limited by bone, air (lung, stomach, bowel) and depth of penetration. In the abdomen, this system can "see" around bowel and spine by adding together the full set of images. There is no workaround for the head or lungs and you'll notice that's why they didn't offer any pictures of those areas. It also means it won't be great at screening inside the stomach, intestine, or colon. I also note the volunteers appear fairly skinny. Ultrasound is always more limited in heavier patients.
4) "But AI can fix it!"...not really. Current DL-based reconstruction techniques require at least some undersampling of a region in order to reconstruct the image. You'll get a lovely picture of the outside of the skull. I can AI-upsample a fuzzy photograph but that doesn't mean what comes out of it actually existed. We have a variant of this issue already with MRI DL reconstruction.
5) "But this is better than MRI in the 1970s!" Yes, true. But the competition is not 1970s MRI, it's modern CT/MRI/US and most especially low-field MRI. For brain, for example, low-field MRI is already diagnostic quality and doesn't need shielding. A low-field scanner costs 50k and can be used in an ICU or put in a van. Why would I send a patient to get an experimental full body US when there's whole body MRI available that's already diagnostic quality? science.org/doi/abs/10.1126/…
6) "The FDA has no idea how to regulate this." This one made me laugh. There's an entire set pathway for this. Commercial ultrasound tomography already exists as an easy reference of a similar technology in the application. If they haven't submitted to the FDA, it's because they plan to try at a later date, or because they're not planning on submitting it at all.
Do I think this is new and exciting? Yes. It looks like it's going to be great for body composition, and I do think there will be improvement in the future.
Is it currently medical-grade diagnostic quality? No, not based on what they showed us. Apparently in-person there was a great hand demo. I don't see why that would be an improvement over routine US or MRI in visualizing hand soft tissues.
To quote @khakrish: "It feels like all the same problems as full body MRI with the added problem of an unproven imaging modality and no FDA clearance."
Simeng Zhu retweeted
I spent a bunch of time this week getting my Nvidia DGX Spark working in Ai2's post-training repo (open-instruct) for a local RL debugging machine. It was quite hard due to cuda 13 requirement and not many VLLM wheels.
github.com/natolambert/dgx-s…
Simeng Zhu retweeted
The linked paper is a nice document and summary product, but let's emphasize a few highlights:
1. Statement 16, strong consensus: ctHPVDNA should supplement conventional surveillance tools, rather than reducing or replacing them. Natural corollary: if it is not reducing or replacing surveillance, what is the point?
2. Statement 9, strong consensus: Detectable ctHPVDNA without clinical or radiographic evidence of disease often increases patient distress.
3. Statement 5, strong consensus: Large-scale, prospective randomized controlled trials are necessary to validate ctHPVDNA's role in HPV+ oropharyngeal cancer management. I would change that statement from validate to determine. Validate assumes it has a role today, but as the document states, it doesn't reduce or replace any currently established surveillance tools.
There are so many exciting ways that ctHPVDNA may influence care (screening/diagnosis, de-escalation, non-imaging-based surveillance) but these strategies need to be established in prospective randomized trials.
The California Head & Neck Consortium released the first multidisciplinary consensus recommendations on the use of circulating tumor HPV DNA in HPV+ oropharyngeal carcinoma. The panel of 33 experts representing 15 institutions reached strong consensus that a tool like the NavDx® test should be incorporated into routine surveillance.
The consensus recommendations also included:
Using an option like the NavDx test improves time to recurrence detection vs. conventional surveillance tools, but should supplement these methods, not reduce or replace them.
The recommended time for a patient’s first post-treatment test is 3 months.
Serial testing should be performed in conjunction with conventional surveillance every 3 months in the first 2 years post-treatment and every 6 months in years 3-5.
For patients with a single positive post-treatment test where no clinical or radiographic evidence of disease is present, the best time to repeat the test is in one month.
Earlier molecular detection of locoregional or oligometastatic disease should improve outcomes.
These recommendations reinforce real-world clinical validation and value of new technologies like the NavDx test in earlier detection of molecular residual disease and recurrence of HPV+ oropharyngeal cancer. Access the full publication here: bit.ly/3MrPgeG
#ctHPVDNA #HeadAndNeckCancer #Oncology #MRD #NavDx #CancerSurveillance #hncancer
Simeng Zhu retweeted
Today, we successfully implanted the first ever patient with diffusing alpha emitter brachytherapy for a brain tumor. This is the first in human alpha emitting Radium-224.
@OhioStateRadOnc @OSUCCC_James @NeurosurgeryOSU @ASTRO_org @ESTRO_RT @NeuroOnc @CNS_Update Brad Elder.
Simeng Zhu retweeted
1/
Just published in @IJROBP: “Histological Classifier of Radiosensitivity to Spine SBRT.”
doi.org/10.1016/j.ijrobp.202…
Simeng Zhu retweeted
Congrats to all our team @OSUCCC_James @OhioStateRadOnc, 3rd in LAPS sites for NRG accruals! And our CNS team continues to lead for trials to answer these important questions!
@joshuapalmermd @DrRajuRaval @SimengZhuMD
Congrats, Josh! Great to be part of the CNS team here at OSU.
Mid-career achievement finally passed 5000 citations and 200 published manuscripts. Thankful for our excellent CNS team at OSU and all my worldwide collaborators!!@OhioStateRadOnc
Simeng Zhu retweeted
Great to see our CNS/Peds director @joshuapalmermd! Making a huge difference for our patients in the state of Ohio and elsewhere through his prolific work @OhioStateRadOnc
Honored to participate at The James Ambassadors Foundation Fall Celebration. Thanks to our @OSUCCC_James Ambassadors for supporting research. “Precision, Collaboration, innovation, translational research personalization and hope are in the future of cancer care” (@David_Cohn_MD)
Simeng Zhu retweeted
BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Physics to John J. Hopfield and Geoffrey E. Hinton “for foundational discoveries and inventions that enable machine learning with artificial neural networks.”
Simeng Zhu retweeted
Great to see Darrion Mitchell representing the HN team @OhioStateRadOnc at the HN PRO session! I’m sure it was an excellent talk on management of late toxicities! @EmileGogineni @DukagjinBlakaj @SimengZhuMD @SungJunMa
Back for the last leg of the PRO sessions - H&N toxicity prevention and radiopharm in the community setting #ASTRO2024 @ShaunaRadOnc
Simeng Zhu retweeted
Great time at brain mets PRO @ASTRO_org w/ @stuxrt and @wgbreen, reviewing prevention/diagnosis/management of radionecrosis and @OhioStateRadOnc experience w/ Boswellia! Thanks to @BeantGill118 and Avani Rao for organizing!
Simeng Zhu retweeted
Below is a list of "Never Words" to avoid around patients. 🧐 doi.org/10.1016/j.mayocp.202…




































